Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rocuronium bromide · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 0.45 mg/kg Zemuron | EXPERIMENTAL | 0.45 mg/kg Zemuron |
| 0.6 mg/kg Zemuron | ACTIVE_COMPARATOR | 0.6 mg/kg Zemuron |
| 1.0 mg/kg Zemuron | EXPERIMENTAL | 1.0 mg/kg Zemuron |
| 0.6 mg/kg intubation dose + sevoflurane | EXPERIMENTAL | - |
| 0.9 mg/kg intubation dose + sevoflurane | EXPERIMENTAL | - |
| 0.6 mg/kg intubation dose + propofol | EXPERIMENTAL | - |
| 0.9 mg/kg intubation dose + propofol | EXPERIMENTAL | - |
| 0.6 mg/kg intubation dose under sevoflurane | EXPERIMENTAL | - |
| 0.9 mg/kg intubation dose under sevoflurane | EXPERIMENTAL | - |
| continuous dose following 0.6 mg/kg intubation dose + propofol | EXPERIMENTAL | - |
| continuous dose following 0.9 mg/kg intubation dose + propofol | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Rocuronium bromide (Zemuron) | DRUG | A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation. |
| Rocuronium bromide (Org 9426) | DRUG | 0.6 mg/kg injection intubation dose |
| Sevoflurane | DRUG | 0.5-2.0% intravenous maintenance anesthesia |
| Propofol | DRUG | 4-10 mg/kg/hr maintenance anesthesia |
| Rocuronium bromide | DRUG | Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation |
Inclusion Criteria: * Male and female subjects from birth up to 17 years of age who will be scheduled for surgery under general anesthesia. Exclusion Criteria: * Subjects whose parent(s) or legal guardian(s) are not willing to give written consent and where applicable, subjects who have not given...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan, Astra-Zeneca |
| Cardinal Health, Inc. | CAH | 1 | - | Undisclosed |
| Medtronic Plc | MDT | 1 | N/A | Undisclosed |
Rocuronium bromide is used for anesthesia and muscle relaxation. It is a small molecule being developed by Merck & Company, Inc. (MRK) and is currently in Phase 3 clinical development. The drug is intended to provide muscle relaxation during surgical procedures under general anesthesia.
Rocuronium bromide is a neuromuscular blocking agent that works by blocking the action of acetylcholine at the neuromuscular junction, leading to muscle relaxation. It is used to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.
Rocuronium bromide is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 3 clinical development for use in anesthesia and muscle relaxation.
Rocuronium bromide is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied for its efficacy and safety in providing muscle relaxation during anesthesia.
Rocuronium bromide has completed three Phase 3 clinical trials. These include NCT00124722, which compared different intubating doses in pediatric and adolescent subjects under general anesthesia with 207 participants, and NCT00984633 and NCT00988520, which studied bolus maintenance doses and continuous intravenous infusion, respectively, with 40 and 38 participants.
Yes, Rocuronium bromide is also known as Zemuron. The clinical trial NCT00124722, which studied different intubating doses of the drug in pediatric and adolescent subjects, refers to Zemuron in its title. This alternative name is used in some clinical and commercial contexts.